ALRN-6924 in Pediatric Cancer
Contact
Description
This study involves taking a study drug called ALRN-6924. ALRN-6924is an investigational cancer treatment that activates p53, which suppresses thegrowth of tumors by blocking proteins in the cell called MDM2 and MDMX thatinhibit p53 from doing its job. The overall goals of thisstudy are to evaluate the side effects and benefits of ALRN-6924 in patientswith relapsed or treatment refractory solid tumor or brain tumor, and to determinethe best dose of ALRN-6924 for children and adolescents. This study will alsolook at how the body breaks down ALRN-6924 by measuring the amount of ALRN-6924in the blood over time after a dose.
Eligibility and criteria
What to expect
This study will enroll male and female patients who are between 1 and 21years of age and who have a relapsed or treatment refractory solid tumor orbrain tumor. Subjects will receive ALRN-6924 intravenously (by IV). Drugs will be given to try to prevent nausea andvomiting before each ALRN-6924 dose. Study visits will also include thefollowing assessments: blood tests, collection of cerebrospinal fluid (iflumbar puncture is already being performed), and collection of tumor biopsytissue (if tumor biopsy is already being performed).
We need families like you
Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.